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Abstract
Background: In Italy, HBV vaccination is recommended and offered free of charge through the National
Health Service to selected population groups – e.g., family members of an HBsAg carrier, healthcare
workers, newborns and those who were 12-years old in 1991. However, a significant proportion of cases
of acute hepatitis B still occur in Italy among persons who should have been vaccinated. We analysed HBV
sero-prevalence data of two vaccination target populations (people born after 1980 and household
contacts of an HBV carrier) living in a southern Italian area in order to evaluate HBV vaccine coverage and
its possible determinants.
Methods:  Between 2003 and 2006, we carried out a cross-sectional, population-based, sero-
epidemiological survey on HBV infection on 4496 randomly selected individuals (aged 20 years or more)
from the general population of the province of Naples. Sera were tested for antibodies to hepatitis B core
antigen (anti-HBc) and to hepatitis B surface antigen (anti-HBsAg) by commercial immunoassays.
Prevalence of past or current HBV infection and of HBV vaccination-induced immunity was calculated in
two vaccination target populations. To analyze the association of epidemiological and socioeconomic
characteristics with HBV vaccination of household contacts, we calculated crude and multiple logistic
regression (MLR) odds ratio (OR).
Results:  Prevalence of HBV vaccine-induced immunity (anti-HBs alone) was much lower among
household contacts (25%) than among those who had been targeted for universal adolescent vaccination
(81.6%). Male sex, older age, unemployment and lower education levels were associated to lower
immunization rates.
Conclusion: Understanding the different uptake of hepatitis B vaccination in these populations may
provide useful information for optimizing vaccination campaigns in other contexts. Our data clearly
demonstrated the need of improving the uptake of vaccination for household contacts of HBV carriers.
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Background
In Italy, since 1984 HBV vaccination has been recom-
mended and offered free of charge by the National Health
Service to high-risk groups – e.g., family members of
HBsAg carriers, healthcare workers. In 1991, vaccination
became mandatory for all newborns and for twelve year-
old adolescents [1]. According to the Acute Hepatitis
National Surveillance System (SEIEVA), the incidence of
acute hepatitis B decreased from 5.1 cases per 100,000
persons in 1991 to 1.3 per 100,000 persons in 2005.
However, a significant proportion of cases of acute hepa-
titis B still occur in Italy among persons who should have
been vaccinated [1].
To provide further insight into missed opportunities for
HBV prevention in Italy, we analyzed HBV sero-preva-
lence data of two target populations for HBV vaccination,
i.e., people born after 1980 and household contacts of an
HBV carrier, collected in a population-based survey on
viral hepatitis infections [2]. The survey was conducted in
the province of Naples, an area of southern Italy with the
highest incidence rates of liver cancer in Europe and
where about 90% of liver cancers are attributable to infec-
tion with hepatitis C virus (HCV) and/or HBV [3].
Aim of this analysis was to compare HBV vaccination cov-
erage between two target populations.
Methods
Between 2003 and 2006, we carried out a cross-sectional,
population-based, sero-epidemiological survey on hepati-
tis virus infections in the province of Naples. Methods of
this survey have been previously described in detail [2].
Briefly, 4496 randomly selected individuals (aged 20
years or more), after signing informed consent, donated a
blood sample and completed a standardized question-
naire, which included questions on HBV infected house-
holds and on HBV vaccination. The study protocol
conformed to the 1975 Declaration of Helsinki and had
been approved by the CCR Board of Ethics.
Sera were tested for hepatitis B surface antigen (HBsAg)
and for antibodies to HBV-core antigen (anti-HBc) using
enzyme immunoassays (Cobas Core ll, Roche Diagnos-
tics, Indianapolis, IN, USA); for antibodies to HBV-surface
antigen (anti-HBs) by enzyme immunoassays (Anti-HBs
Quant EIA II – Roche Diagnostics): samples with a reactiv-
ity >10 IU/L were considered positive [4].
For the purpose of this analysis, positive results for anti-
HBc were considered to indicate past or current HBV
infection, while positivity for anti-HBsAg (anti-HBs) only
was considered indicative of HBV vaccination-induced
immunity. Individuals who tested negative for all HBV
serological markers were considered as non immune/non
infected.
Statistical analysis
Prevalence of past or current HBV infection and of HBV
vaccination-induced immunity was calculated in two vac-
cination target populations i.e. persons born ≥ 1980 and
household contacts of an HBV carrier. To analyze the asso-
ciation of epidemiological and socioeconomic character-
istics with HBV vaccination of household contacts, we
compared, among those born before 1980, individuals
with immune protection with those not immune/not
infected. As a measure of association, we calculated odds
ratio (OR) and multivariate logistic regression odds ratio
(MLR-OR) and their 95% confidence intervals (95% CI).
The MLR was adjusted for gender, age, as a priori chosen
variables, and for variables significantly associated with
immune protection in univariate analysis. We also per-
formed a sensitivity analysis considering as "vaccinated",
subjects that reported to have been vaccinated but testing
negative for anti-HBs.
To evaluate agreement between vaccination status accord-
ing to self-report and that obtained from laboratory
results, we calculated the percentage of agreement and the
kappa (k) statistic. Statistical analyses were performed
using SPSS package (version 15.00 SPSS Inc., Chicago, Illi-
nois).
Results
Among 577 study subjects born between 1980 and 1983
who should have been vaccinated at the age of 12 years,
the overall prevalence of past or current HBV infection
was 3.3%. The prevalence of HBV vaccination-induced
immunity was 81.6% (471/577).
Among 247 individuals born before 1980 who reported
living with an HBV carrier, the rate of anti-HBs seroposi-
tivity was 15.4% (38/247). Excluding 95 subjects with
past or current HBV infection, the prevalence of anti-HBs
seropositivity among households was 25% (38/152). This
proportion was significantly lower than that recorded
among those born between 1980 and 1983 (p = 0.0000).
The overall agreement among these individuals between
self-reported and serologic evidence of vaccination was
87.2%, with a k = 0.58 (p = 0.0000).
The prevalence of HBV vaccination-induced immunity
among not infected household contacts born before 1980
according to socio-demographic characteristics is pre-
sented in table 1. In the final multiple logistic regression
model (including terms for gender, age, education and
occupation) socio-economic factors significantly associ-
ated with HBV vaccination were female gender, youngerBMC Infectious Diseases 2009, 9:86 http://www.biomedcentral.com/1471-2334/9/86
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age and being employed. Sensitivity analysis confirmed
these associations (data not shown).
Discussion
In our study, HBV vaccination coverage significantly dif-
fered between two target populations studied in the same
geographical area at high HBV prevalence. Vaccine cover-
age among individuals who should have been vaccinated
at the age of 12, in agreement with previous surveys [5,6],
was quite high (81.6%) although lower than 93.6% cov-
erage measured globally in Italy [6].
In contrast, the prevalence of anti-HBs seropositivity
among household contacts of an HBV carrier was 15.4%,
reaching 25% if we exclude those already infected, and we
found that 46.1% of contacts were still HBV susceptible.
Our data are similar to those found in a study in the
United Kingdom showing that only 27% of susceptible
contacts were immunized [7]. Understanding the differ-
ent uptake of HBV vaccination in these two populations
may provide useful information for optimizing HBV vac-
cination campaigns in other contexts.
In vaccination campaign for 12 year-old individuals, vac-
cine candidates were directly contacted by health districts
vaccination units, after identification through lists of resi-
dents or lists of school attendees. Moreover a vaccination
certificate was required for eighth grade final examination
[5]. In contrast, vaccination for household contacts relies
on referral to vaccination units of candidates by family
physicians or by other health care providers involved in
the diagnosis and care of HBV infection. Indeed, there is
evidence of a low level of attention on family spread of
HBV infection both by many patients and their physicians
[8,9]. We could then speculate that active involvement of
vaccination units may have been a key factor in promot-
Table 1: HB vaccination-induced immunity among not infected households born before 1980 according to socio-demographic 
characteristics
Vaccine-induced immunitya
Not Vaccinatedb N (%) Vaccinatedc N (%) OR (95% CI) MLR-ORd (95% CI)
Total 114 (75.0) 38 (25.0)
Gender
Male 47 (81.0) 11 (19.0) 1 1
Female 67 (71.3) 27 (28.7) 1.7 (0.8–3.8) 2.6 (1.0–6.6)
Age
for each 10 year increase 0.42 (0.40–0.45) 0.60 (0.38–0.87)
Education
0–8 years 74 (81.3) 17 (18.7) 1 1
≥ 9 years 40 (65.6) 21 (34.4) 2.3 (1.1–4.8) 1.4 (0.6–3.3)
Current employment
Employed 40 (67.8) 19 (32.2) 1 1
Unemployed 10 (83.3) 2 (16.7) 0.4 (0.1–2.1) 0.2 (0.0–0.9)
Student, retired, housewife 55 (84.6) 10 (15.4) 0.4 (0.2–0.9) 0.4 (0.1–1.0)
Unknown 9 (56.2) 7 (43.8) 1.6 (0.5–5.1) 1.3 (0.4–4.4)
Marital status
Ever Married 95 (77.2) 28 (22.8) 1
Single 14 (63.6) 8 (36.4) 1.9 (0.7–5.1)
Unknown 5 (71.4) 2 (28.6) 1.4 (0.2–7.4)
Infected family member
Partner 24 (80.0) 6 (20.0) 1
Parent 26 (63.4) 15 (36.6) 2.3 (0.8–6.9)
Other 34 (75.6) 11 (24.4) 1.3 (0.4–4.0)
Unknown 30 (83.3) 6 (16.7) 0.8 (0.2–2.8)
a In some items, the sum does not add up to the total because of missing values.
b All markers negative (HBsAg; anti-HBc; anti-HBs)
c Only anti-HBs positive
d Adjusted for gender, age and education and current employmentBMC Infectious Diseases 2009, 9:86 http://www.biomedcentral.com/1471-2334/9/86
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ing access to HBV vaccination. Our study also shows that
individuals' factors may contribute to lack of immuniza-
tion among household contacts of an HBV carrier. In fact
in our study population, older persons, those unem-
ployed and those with lower education were less likely to
have HBV vaccination-induced immunity. These observa-
tions suggest that targeted strategies should be imple-
mented to reach these persons.
We identified some potential limitations and weaknesses
of our study. Considering anti-HBs a proxy of vaccination
can introduce a misclassification of outcome because in
some HBV vaccinated individuals antibody titres decline
with time after the first vaccination, to below the level of
10 IU/L and some are non-responders [4]. On the other
hand there was a good agreement between serological
results and self reported data on vaccination, similar asso-
ciations were found when we used self-reported vaccina-
tion as an outcome in the analysis instead of anti-HBs
positivity. Another limitation of this study is that we have
defined "household contacts of an HBV carrier" on the
basis of a self-administered questionnaire but we do not
have any clinical confirmation of this information.
Conclusion
In conclusion, our data clearly demonstrated the need of
improving the uptake of vaccination for household con-
tacts of HBV carriers. Active recruitment of potential can-
didates into vaccination programs may be needed to
achieve this goal. In this context information campaigns
for HBV infected patients and health care providers may
be needed and implementation of centralised, hospital-
based immunisation programs, including home visits,
should be considered [10].
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